Background: Low antigravity muscle mass is strongly associated with poor prognosis in patients with chronic obstructive pulmonary disease (COPD). However, the significance of longitudinal changes in antigravity muscle mass remains unclear in patients with COPD. Objectives: The aims of this study were to investigate the factors associated with the longitudinal loss of antigravity muscles and whether the accelerated loss of these muscles has a negative impact on prognosis. Methods: This study was part of a prospective observational study at Kyoto University. We enrolled stable male patients with COPD who underwent longitudinal quantitative CT analysis of the cross-sectional area of the erector spinae muscles (ESMCSA) at an interval of 3 years. The associations between the rate of change in ESMCSA (%ΔESM) and clinical parameters, such as anthropometry, symptoms, lung function, exacerbation frequency, and all-cause mortality, were investigated. Results: In total, 102 stable male COPD patients were successfully evaluated in this study (71.3 ± 8.3 years, GOLD stage I/II/III/IV = 20/47/28/7 patients). ESMCSA significantly decreased from 30.53 to 28.98 cm2 (p < 0.0001) in 3 years, and the mean %ΔESM was 5.21 ± 7.24%. The rate of survival during the observation period was 85.3% (87/102). Patients with an accelerated decline in ESMCSA (n = 31; more than double the mean rate of decline) had a significantly higher frequency of moderate-to-severe exacerbations during the interval (p = 0.015). They also had significantly worse survival (p = 0.035 by log-rank test). A multivariate Cox proportional hazard model showed that lower ESMCSA and greater %ΔESM decline were independently and significantly associated with mortality. Conclusions: Frequent exacerbations were related to the loss of antigravity muscles in COPD patients. The accelerated loss of antigravity muscles was associated with a poor prognosis.

1.
the Global Strategy for the Diagnosis
. Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)
2019
[accessed 2019 Apr 22]. Available from: http://www.goldcopd.com
2.
Schols
AM
,
Broekhuizen
R
,
Weling-Scheepers
CA
,
Wouters
EF
.
Body composition and mortality in chronic obstructive pulmonary disease
.
Am J Clin Nutr
.
2005
Jul
;
82
(
1
):
53
9
.
[PubMed]
0002-9165
3.
Ikezoe
T
,
Mori
N
,
Nakamura
M
,
Ichihashi
N
.
Effects of age and inactivity due to prolonged bed rest on atrophy of trunk muscles
.
Eur J Appl Physiol
.
2012
Jan
;
112
(
1
):
43
8
.
[PubMed]
1439-6319
4.
Waschki
B
,
Kirsten
A
,
Holz
O
,
Müller
KC
,
Meyer
T
,
Watz
H
, et al.
Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study
.
Chest
.
2011
Aug
;
140
(
2
):
331
42
.
[PubMed]
0012-3692
5.
Tanimura
K
,
Sato
S
,
Fuseya
Y
,
Hasegawa
K
,
Uemasu
K
,
Sato
A
, et al.
Quantitative Assessment of Erector Spinae Muscles in Patients with Chronic Obstructive Pulmonary Disease. Novel Chest Computed Tomography-derived Index for Prognosis
.
Ann Am Thorac Soc
.
2016
Mar
;
13
(
3
):
334
41
.
[PubMed]
2329-6933
6.
Langen
RC
,
Gosker
HR
,
Remels
AH
,
Schols
AM
.
Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease
.
Int J Biochem Cell Biol
.
2013
Oct
;
45
(
10
):
2245
56
.
[PubMed]
1357-2725
7.
Cielen
N
,
Maes
K
,
Gayan-Ramirez
G
.
Musculoskeletal disorders in chronic obstructive pulmonary disease.
2014
;2014:965764.
8.
Ehsan
M
,
Khan
R
,
Wakefield
D
,
Qureshi
A
,
Murray
L
,
Zuwallack
R
, et al.
A longitudinal study evaluating the effect of exacerbations on physical activity in patients with chronic obstructive pulmonary disease
.
Ann Am Thorac Soc
.
2013
Dec
;
10
(
6
):
559
64
.
[PubMed]
2329-6933
9.
Donaldson
GC
,
Wilkinson
TM
,
Hurst
JR
,
Perera
WR
,
Wedzicha
JA
.
Exacerbations and time spent outdoors in chronic obstructive pulmonary disease
.
Am J Respir Crit Care Med
.
2005
Mar
;
171
(
5
):
446
52
.
[PubMed]
1073-449X
10.
Terada
K
,
Muro
S
,
Sato
S
,
Ohara
T
,
Haruna
A
,
Marumo
S
, et al.
Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation
.
Thorax
.
2008
Nov
;
63
(
11
):
951
5
.
[PubMed]
0040-6376
11.
Burge
PS
,
Calverley
PM
,
Jones
PW
,
Spencer
S
,
Anderson
JA
,
Maslen
TK
.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
.
BMJ
.
2000
May
;
320
(
7245
):
1297
303
.
[PubMed]
0959-8138
12.
Sasaki
E
,
Nakamura
M
,
Kida
K
.
Reference values for spirogram and blood gas analysis in Japanese non-smoking healthy adults
.
J Jpn Respir Soc.
2001
;(
39
):
383
99
.
13.
Berglund
E
,
Birath
G
,
Bjure
J
,
Grimby
G
,
Kjellmer
I
,
Sandqvist
L
, et al.
Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age
.
Acta Med Scand
.
1963
Feb
;
173
(
2
):
185
92
.
[PubMed]
0001-6101
14.
Tanabe
N
,
Muro
S
,
Hirai
T
,
Oguma
T
,
Terada
K
,
Marumo
S
, et al.
Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease
.
Am J Respir Crit Care Med
.
2011
Jun
;
183
(
12
):
1653
9
.
[PubMed]
1073-449X
15.
Ohara
T
,
Hirai
T
,
Muro
S
,
Haruna
A
,
Terada
K
,
Kinose
D
, et al.
Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD
.
Chest
.
2008
Dec
;
134
(
6
):
1244
9
.
[PubMed]
0012-3692
16.
Nakano
Y
,
Muro
S
,
Sakai
H
,
Hirai
T
,
Chin
K
,
Tsukino
M
, et al.
Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function
.
Am J Respir Crit Care Med
.
2000
Sep
;
162
(
3 Pt 1
):
1102
8
.
[PubMed]
1073-449X
17.
Bernard
S
,
LeBlanc
P
,
Whittom
F
,
Carrier
G
,
Jobin
J
,
Belleau
R
, et al.
Peripheral muscle weakness in patients with chronic obstructive pulmonary disease
.
Am J Respir Crit Care Med
.
1998
Aug
;
158
(
2
):
629
34
.
[PubMed]
1073-449X
18.
Johnson
MA
,
Polgar
J
,
Weightman
D
,
Appleton
D
.
Data on the distribution of fibre types in thirty-six human muscles. An autopsy study
.
J Neurol Sci
.
1973
Jan
;
18
(
1
):
111
29
.
[PubMed]
0022-510X
19.
Engel
WK
.
Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases
.
Arch Neurol
.
1970
Feb
;
22
(
2
):
97
117
.
[PubMed]
0003-9942
20.
Lexell
J
,
Taylor
CC
,
Sjöström
M
.
What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men
.
J Neurol Sci
.
1988
Apr
;
84
(
2-3
):
275
94
.
[PubMed]
0022-510X
21.
Grimby
G
,
Broberg
C
,
Krotkiewska
I
,
Krotkiewski
M
.
Muscle fiber composition in patients with traumatic cord lesion
.
Scand J Rehabil Med
.
1976
;
8
(
1
):
37
42
.
[PubMed]
0036-5505
22.
de Theije
CC
,
Langen
RC
,
Lamers
WH
,
Gosker
HR
,
Schols
AM
,
Kohler
SE
.
Differential sensitivity of oxidative and glycolytic muscles to hypoxia-induced muscle atrophy.
Journal of applied physiology (Bethesda, Md : 1985).
2015
;118(2):200-11.
23.
Alahmari
AD
,
Patel
AR
,
Kowlessar
BS
,
Mackay
AJ
,
Singh
R
,
Wedzicha
JA
, et al.
Daily activity during stability and exacerbation of chronic obstructive pulmonary disease
.
BMC Pulm Med
.
2014
Jun
;
14
(
1
):
98
.
[PubMed]
1471-2466
24.
van den Borst
B
,
Koster
A
,
Yu
B
,
Gosker
HR
,
Meibohm
B
,
Bauer
DC
, et al.
Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?
Thorax
.
2011
Nov
;
66
(
11
):
961
9
.
[PubMed]
0040-6376
25.
Rutten
EP
,
Calverley
PM
,
Casaburi
R
,
Agusti
A
,
Bakke
P
,
Celli
B
, et al.
Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes?
Ann Nutr Metab
.
2013
;
63
(
3
):
239
47
.
[PubMed]
0250-6807
26.
Kim
V
,
Davey
A
,
Comellas
AP
,
Han
MK
,
Washko
G
,
Martinez
CH
, et al.;
COPDGene® Investigators
.
Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study
.
Respir Res
.
2014
Apr
;
15
(
1
):
52
.
[PubMed]
1465-9921
27.
Elbehairy
AF
,
Raghavan
N
,
Cheng
S
,
Yang
L
,
Webb
KA
,
Neder
JA
, et al.;
Canadian Respiratory Research Network
.
Physiologic characterization of the chronic bronchitis phenotype in GOLD grade IB COPD
.
Chest
.
2015
May
;
147
(
5
):
1235
45
.
[PubMed]
0012-3692
28.
Vaes
AW
,
Garcia-Aymerich
J
,
Marott
JL
,
Benet
M
,
Groenen
MT
,
Schnohr
P
, et al.
Changes in physical activity and all-cause mortality in COPD
.
Eur Respir J
.
2014
Nov
;
44
(
5
):
1199
209
.
[PubMed]
0903-1936
29.
Schmidt
SA
,
Johansen
MB
,
Olsen
M
,
Xu
X
,
Parker
JM
,
Molfino
NA
, et al.
The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study
.
BMJ Open
.
2014
Dec
;
4
(
12
):
e006720
.
[PubMed]
2044-6055
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.